It targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide)
For liposomal oral tablets, which contain a protective buffer of fatty acids that resist degradation and destruction, researchers recommend a starting dose of 10 mg, but this may be too small of a dose to see positive effects [14, 15]
Younossi ZM, Corey KE, Lim JK (2021) AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review
They manage chronic conditions
The peptide component of MEDI4166 has been extensively optimised to provide lasting glucose and weight control that is able to better match the antibody PK in combination with a reduced GLP-1R potency and a favourable manufacturability profile
Starting dose and titration speed also affect the timeline